Related Experiment Videos
Neurogenic inflammation in the airways
1Department of Thoracic Medicine, National Heart and Lung Institute, Imperial College School of Medicine, Dovehouse Street, SW3 6LY, London, UK. p.j.barnes@ic.ac.uk
Respiration Physiology
|March 10, 2001
Summary
Neurogenic inflammation, involving neuropeptides, may affect airway diseases like asthma. Direct evidence in humans is limited, but further research into severe airway conditions is warranted.
Area of Science:
- Respiratory Medicine
- Neuroimmunology
- Inflammation Research
Background:
- Sensory neuropeptides like tachykinins and calcitonin gene-related peptide can cause airway inflammation.
- Neurogenic inflammation, triggered by irritants and inflammatory mediators, is established in animal models.
- Its role in human airway diseases such as asthma and COPD remains unclear due to limited direct evidence.
Purpose of the Study:
- To investigate the potential role of neurogenic inflammation in human airway diseases.
- To assess the contribution of sensory neuropeptides to airway inflammation in conditions like asthma and COPD.
Main Methods:
- Review of existing literature on neurogenic inflammation and airway diseases.
- Analysis of clinical studies investigating strategies to block neurogenic inflammation.
- Consideration of animal model findings for relevance to human pathology.
Main Results:
- Neurogenic inflammation is well-documented in animal models of airway irritation and inflammation.
- Direct evidence for sensory neuropeptide involvement in human airway inflammation is scarce.
- Initial clinical trials targeting neurogenic inflammation have yielded unpromising results.
Conclusions:
- The precise role of neurogenic inflammation in human asthma and COPD requires further investigation.
- Future studies should focus on severe airway diseases and employ prolonged study designs.
- Exploring therapeutic strategies that modulate neurogenic inflammation may be beneficial.